News

A study found 3% hypertonic saline nasal irrigation reduced symptoms in allergic rhinitis but offered no significant advantage over isotonic saline.

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This Savvy Stories episode of the Skin of Color Savvy podcast features 4 speakers highlighting the SOCS Clinical Investigators Training Program.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

In this Q&A, Malhotra discusses how tirzepatide impacts obstructive sleep apnea treatment.

New research highlights the benefits of PAP therapy for sleep apnea, showing improvements in blood pressure and cardiometabolic health.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

These phase 3 data, released by MoonLake Immunotherapeutics, highlight week 16 results for patients with hidradenitis suppurativa using sonelokimab.

Denecimig may offer a prophylaxis bleed treatment option for a range of patients across dosing frequencies, age groups, and condition severity.

In this interview at EADV, Bernstein highlights dupilumab’s impact on urticaria activity in individuals with chronic spontaneous urticaria (CSU).

The resubmission is based on results from 5 randomized clinical trials in the ONWARDS type 2 diabetes phase 3a program.

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Recent analyses detail the ongoing risk of hyperkalemia in heart failure patients, highlighting the importance of optimal medication dosing.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

Aficamten shows superior exercise capacity improvements over metoprolol for patients with oHCM.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.

New 96-week data reveals aficamten's significant benefits for patients with nonobstructive hypertrophic cardiomyopathy.

Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.

Guideline-directed medical therapy and SGLT2i use has been associated with reduced total health care costs and a lower risk of hospitalization and death.

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

Patients taking multiple drugs simultaneously receive the same protective effect from finerenone, regardless of their degree of polypharmacy.

New research links marijuana use to higher readmission and mortality rates in heart failure patients.

Recent studies reveal finerenone's superior benefits over traditional MRAs in heart failure, showing reduced mortality and hospitalization rates.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).